| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/01/2007 | WO2007024391A2 Light-activated cation channel and uses thereof |
| 03/01/2007 | WO2007024097A1 PHARMACEUTICAL COMPOSITION, COMPOSITION FOR SCREENING THERAPEUTICS PREVENTING AND TREATING BETA AMYLOID ACCUMULATION IN BRAIN COMPRISING GCPn(GLUTAMATE CARBOXYPEPTIDASE Π) AS AN ACTIVE INGREDIENT AND METHOD FOR SCREENING USING THE SAME |
| 03/01/2007 | WO2007024029A1 Antiviral agent and viral replication inhibitor |
| 03/01/2007 | WO2007024008A1 Preventive or therapeutic agent for side effect based on cytotoxicity of anticancer therapy containing apoptosis inhibition activity-enhancing protein fnk or nucleic acid encoding the same |
| 03/01/2007 | WO2007023776A1 Prophylactic or therapeutic agent for osteoporosis having pharmacological efficacy confirmed in simian model |
| 03/01/2007 | WO2007023479A2 Treatment of central nervous system injury |
| 03/01/2007 | WO2007023243A2 Cleavage of antifolate compounds |
| 03/01/2007 | WO2007023163A1 Polypeptides having antimicrobial activity and polynucleotides encoding same |
| 03/01/2007 | WO2007022784A2 Liquid factor vii composition |
| 03/01/2007 | WO2007022774A1 THERAPEUTICALLY ACTIVE α-MSH ANALOGUES |
| 03/01/2007 | WO2007022668A1 Important lymphocyte activation regulatory protein pkd2 and uses thereof |
| 03/01/2007 | WO2007022635A2 Methods of attenuating prostate tumor growth by insulin-like growth factor binding protein-3 (igfbp-3) |
| 03/01/2007 | WO2007022616A2 Hybrid ultrafast laser surgery and growth factor stimulation for ultra-precision surgery with healing |
| 03/01/2007 | WO2007022557A1 Mimotopes of epstein-barr virus (ebv) epitopes |
| 03/01/2007 | WO2007005389A9 F11 receptor (f11r) antagonists as therapeutic agents |
| 03/01/2007 | WO2007002811A3 Methods and compositions for treating melanoma |
| 03/01/2007 | WO2006127966A3 Compositions and methods for enhancing axon regeneration |
| 03/01/2007 | WO2006119965A3 Growth factor mutants with altered biological attributes |
| 03/01/2007 | WO2006119767A3 Neuritogenic peptides |
| 03/01/2007 | WO2006117241A3 Polypeptide, vaccine and use thereof |
| 03/01/2007 | WO2006116269A3 Antibodies to myostatin |
| 03/01/2007 | WO2006111946A3 Toll-like receptor 14 (tlr14 ) and use thereof |
| 03/01/2007 | WO2006103455A3 Use of calcitonin as combined treatment therapy for the management of inflammatory disease conditions |
| 03/01/2007 | WO2006091729A3 Revascularization of ischemic retinal tissue and screening method therefor |
| 03/01/2007 | WO2006091727A3 Single branch heparin-binding growth factor analogs |
| 03/01/2007 | WO2006086799A3 Prion-specific peptide reagents |
| 03/01/2007 | WO2006081573A3 Homogeneous preparations of il-31 |
| 03/01/2007 | WO2006081259A3 Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis |
| 03/01/2007 | WO2006072048B1 Compositions and methods for identifying modulators of hausp |
| 03/01/2007 | WO2006069220A3 Modified human growth hormone |
| 03/01/2007 | WO2006057003A3 Induction of neurogenesis and stem cell therapy in combination with copolymer 1 |
| 03/01/2007 | WO2006042249A3 Methods and compositions for treating migraine pain |
| 03/01/2007 | WO2006029343A3 Peptides that selectively home to heart vasculature and related conjugates and methods |
| 03/01/2007 | WO2006013552A3 Articles of peptide nanostructures and method of forming the same |
| 03/01/2007 | WO2005055983A3 Method of preparation of mixed phase co-crystals with active agents |
| 03/01/2007 | WO2005048920A3 Methods and compositions for protecting against cataract development associated with vitrectomies |
| 03/01/2007 | WO2005017120A3 Mracs as modifiers of the rac pathway and methods of use |
| 03/01/2007 | WO2005017107A3 Specific binding agents to hepatocyte growth factor |
| 03/01/2007 | WO2004101023A3 A method for altering insulin pharmacokinetics |
| 03/01/2007 | WO2004011617A3 Identification of a novel bitter taste receptor, t2r76 |
| 03/01/2007 | US20070050856 Use of protein products for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| 03/01/2007 | US20070050855 Immunoglobulin fusion comprising blood glycoprotein with reduced glycosylation for use in prevention and treatment of septic shock, cachexia, viral and parasitic infection, autoimmune, arthritic and/or graft rejection |
| 03/01/2007 | US20070049743 Novel nucleic acids and polypeptides |
| 03/01/2007 | US20070049740 Mammalian transforming growth factor beta-9 |
| 03/01/2007 | US20070049737 Homogeneous preparations of il-28 and il-29 |
| 03/01/2007 | US20070049735 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070049729 Interleukin-17 receptor homologue |
| 03/01/2007 | US20070049549 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070049548 Methods of treating cancer using il-21 |
| 03/01/2007 | US20070049545 Antisense modulation of fibroblast growth factor receptor 3 expression |
| 03/01/2007 | US20070049544 Antisense IAP nucleobase oligomers and uses thereof |
| 03/01/2007 | US20070049541 Administering oligonucleotide containing optimal nucleotide binding site for the transcription factor for therapy of disease associated with hyper-activated signal transduction pathways, particularly malignancy |
| 03/01/2007 | US20070049536 3-Azabicyclo[3.1.0]hexane-amide derivatives; human T-cell leukemia/lymphoma and lymphadenopathy associated virus, AIDS, cytomegalovirus (CMV) and Epstein-Barr virus (EBV), liver disease such as alcoholism and primary biliar cirrhosis |
| 03/01/2007 | US20070049535 Preventive/remedy for diabetic complications using oligopeptide |
| 03/01/2007 | US20070049534 Urinary track diseases; analgesics; antiinflammatory agents; gastrointestinal disorders; premenstrual tension; respiratory system disorders; incotinence |
| 03/01/2007 | US20070049533 Analogs of peptides corresponding to class I major histocompatibility complex (MHC)-restricted T-cell epitopes that contain amino acid substitutions of norleucine and/or norvaline; intranodal administration a an immunopotentiating agent |
| 03/01/2007 | US20070049532 Selecting by phage display a peptide that binds to nerve growth factor (NGF), and preparing a fusion protein with an Fc domain; biological half-life increases |
| 03/01/2007 | US20070049531 GLP-1 agonist and cardiovascular complations |
| 03/01/2007 | US20070049530 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070049529 Reducing the growth of cancer cells in a mammal by administering polypeptide of the invention; |
| 03/01/2007 | US20070049528 Nucleotide sequence coding polypeptide for use in the treatment cell proliferative disorders; detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo |
| 03/01/2007 | US20070049527 Nucleotide sequences coding cytokine receptor for identifying modulators for treating blood disorders associated with cancer treatment |
| 03/01/2007 | US20070049526 using Zven1 and Zven2 polypeptides to increase chemokine production for treating intestinal motility disorders and improving gastrointestinal funciton |
| 03/01/2007 | US20070049525 Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
| 03/01/2007 | US20070049524 Soluble zcytor21, anti-zcytor21 antibodies and binding partners and methods of using in inflammation |
| 03/01/2007 | US20070049523 Liquid composition of modified factor VII polypeptides |
| 03/01/2007 | US20070049522 Perioperative injection of a polypeptide preferential inhibitor of kallikrein, rather than aprotinin, for cardiopulmonary bypass surgery or coronary artery bypass grafting |
| 03/01/2007 | US20070049521 treating osteoporosis to increase osteogenesis in mammal; biodrug polypeptide for treating bone disorders; osteocrin, a bone secreted protein with prohormone like characteristics; preparing a transgenic non-human mammal with elevated Ostn protein levels in osteoblasts cells, increased long bone length |
| 03/01/2007 | US20070049520 Method of using retro inverso peptides derived from leukemia inhibitory factor |
| 03/01/2007 | US20070049519 Bactericides with antibacterial activity and an improved mammalian safety profile; exhibit reduced tissue accumulation and/or nephrotoxicity when administered to mammals |
| 03/01/2007 | US20070049518 Novel method of treatment of inflammatory skin conditions |
| 03/01/2007 | US20070049517 Use of hyperpolymeric hemoglobin for the treatment of pulmonary edema |
| 03/01/2007 | US20070049516 Use of Insulin for the Treatment of Cartilaginous Disorders |
| 03/01/2007 | US20070049515 Therapeutic agent for diabetes containing insulin resistance improving agent |
| 03/01/2007 | US20070049514 Resonance modulator for diagnosis and therapy |
| 03/01/2007 | US20070048853 Carnitine palmitoyltransferase II crystals |
| 03/01/2007 | US20070048845 Cytokine zalpha11 ligand fusion proteins |
| 03/01/2007 | US20070048844 Produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins; has anti-hepatitis activity; culturing |
| 03/01/2007 | US20070048843 Homogeneous preparations of IL-28 and IL-29 |
| 03/01/2007 | US20070048840 Human Zven polynucleotides |
| 03/01/2007 | US20070048835 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048834 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048833 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048832 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048831 Cytokine receptor zcytor17 multimers |
| 03/01/2007 | US20070048830 Polynucleotide that encodes a protein composed of a first polypeptide disulfide-bonded to a second polypeptide that stimulates proliferation, differentiation, or migration of mesenchymal cells; monoclonal and single-chain antibodies; activating a cell-surface platelet-derived growth factor receptor |
| 03/01/2007 | US20070048829 polynucleotide that encode polypeptides having mitogenic activity on human aortic smooth muscle cells |
| 03/01/2007 | US20070048828 Comprises fusion protein comprising platelet derived growth factor for treating connective tissue, tumor and bone disorders; used to stimulate the production of bone and/or connective tissue in both humans and non-human animals |
| 03/01/2007 | US20070048827 Mammalian transforming growth factor beta-9 |
| 03/01/2007 | US20070048826 Soluble zcytor14, anti-zcytor14 antibodies and binding partners and methods of using in inflammation |
| 03/01/2007 | US20070048822 activating tyrosine phosphorylation of ErbB4 in an ErbB4-expressing cell by administering to the cell a polypeptide comprising the amino acid sequence of neuregulin 3 |
| 03/01/2007 | US20070048820 Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion |
| 03/01/2007 | US20070048811 Tumor suppressor designated TS10q23.3 |
| 03/01/2007 | US20070048805 Methods of using Zven antibodies |
| 03/01/2007 | US20070048794 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 03/01/2007 | US20070048791 CRYSTAL STRUCTURES AND MODELS FOR Fc RECEPTORS AND USES THEREOF IN THE DESIGN OR IDENTIFICATION OF Fc RECEPTOR MODULATOR COMPOUNDS |
| 03/01/2007 | US20070048778 determining the amount of a polynucleotide sequence or a fragment of at least 20 consecutive nucleotides in a test sample and comparing the amount with that from a control, wherein an increase indicates a gastrointestinal disorder |
| 03/01/2007 | US20070048772 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 03/01/2007 | US20070048382 for use in spinal surgery; spray-dried hydroxyapatite, radical donor (benzoyl peroxide) and polymethyl methacrylate |
| 03/01/2007 | US20070048381 Methods for promoting growth of bone, ligament, and cartilage |